TY - JOUR
T1 - An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma
AU - Weller, Dennis R.
AU - Brundage, Richard C.
AU - Balfour, Henry H.
AU - Vezina, Heather E.
PY - 2007/4/1
Y1 - 2007/4/1
N2 - An efficient, isocratic high performance liquid chromatography (HPLC) method for determining human immunodeficiency virus (HIV) non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) in plasma is advantageous for laboratories participating in clinical trials and therapeutic drug monitoring (TDM) programs, or conducting small animal research. The combination of isocratic reversed phase chromatography using an S-3, 3.0 mm × 150 mm column along with low plasma volume (200 μl), rapid liquid-liquid extraction, and detection at a single wavelength (212 nm) over a short run time makes this method valuable. Within and between assay variability ranges from 0.8 to 3.5% and 1.2-6.2%, respectively. Accuracy ranges from 91.0 to 112.8% for four quality controls (50, 100, 1000, and 10,000 ng/ml) for all drugs measured (efavirenz, nevirapine, amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir).
AB - An efficient, isocratic high performance liquid chromatography (HPLC) method for determining human immunodeficiency virus (HIV) non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) in plasma is advantageous for laboratories participating in clinical trials and therapeutic drug monitoring (TDM) programs, or conducting small animal research. The combination of isocratic reversed phase chromatography using an S-3, 3.0 mm × 150 mm column along with low plasma volume (200 μl), rapid liquid-liquid extraction, and detection at a single wavelength (212 nm) over a short run time makes this method valuable. Within and between assay variability ranges from 0.8 to 3.5% and 1.2-6.2%, respectively. Accuracy ranges from 91.0 to 112.8% for four quality controls (50, 100, 1000, and 10,000 ng/ml) for all drugs measured (efavirenz, nevirapine, amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir).
KW - HIV
KW - HPLC-UV
KW - Isocratic
KW - Liquid-liquid extraction
KW - Non-nucleoside reverse transcriptase inhibitors
KW - Protease inhibitors
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=33947366781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947366781&partnerID=8YFLogxK
U2 - 10.1016/j.jchromb.2006.10.022
DO - 10.1016/j.jchromb.2006.10.022
M3 - Article
C2 - 17081812
AN - SCOPUS:33947366781
SN - 1570-0232
VL - 848
SP - 369
EP - 373
JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
IS - 2
ER -